The share price is ridculously cheap down here.
Gary doesn't want to spend anymore money than he has to on SNT 6302 atm - even though like you he knows its a winner.
The easiest shot at goal is SNT-5505 for myelofibrosis. By the 9th December or thereabouts we will have a definitive Phase 2 trial result which by all accounts will be positive and hence the presentation at the prestigous ASH conference in San Diego. If this is positive you can assume that the German Myelodysplastic Syndrome phase 2 trial results will also be positive.
Once these results come out the company is confident deals with big pharma will be done and funds will be available to pursue Skin Scarring with SNT-6302.
Its all about keeping dilution to a minimum.
SNT5505 is a US$4.2 bil market.
Any deal could be a $1 bil plus. This is what Hashan ( I back the smart money) is banking on. He has done his due diligence which would be a lot more extensive than any of us could do and he loaded the truck.
The share price is ridculously cheap down here.Gary doesn't want...
Add to My Watchlist
What is My Watchlist?
